This is a snippet of the transcript, sign up to read more.
So just before 2020, around 2018 or 2019, Bruker released the mass spec timsTOF. Before that, Bruker was honestly struggling a bit in mass spectrometry. They were trying to survive, but when the timsTOF came out, it became really powerful with its scan speed. This means the instrument processes samples very quickly, which is critical. The faster it is, the more proteins we can detect and understand better. I don't want to go into too much detail, but the speed is impressive in mass spectrometry, and it generates a lot of information. Scientists can have less missing information, especially regarding proteins. Bruker's mass spectrometer became very popular around 2019 and continued to be so in 2020 and 2021. Before that, Thermo Fisher dominated the high-end mass spectrometry market. Then, about two or three years ago, Thermo Fisher released a new, extremely powerful and popular mass spectrometer. It's really fast, and that's the Ultra you mentioned. The Thermo Ultra became very popular, with a price of almost $2 million. The price has been continuously increasing, so I believe the profit should also be bigger. Even though I said close to $2 million or $1.5 million, the new Bruker mass spectrometer, like the latest one, is also around $1.4 million. All of them are quite expensive.
This is a snippet of the transcript, sign up to read more.
Software is another area to consider. Typically, there are two different models, a subscription model or a one time payment. But the mass spec companies don't make much money on the software. Several years ago, Thermo released a new software that was initially rather expensive, around $100,000 altogether, with the hardware, but I'm not sure how much the hardware cost. I know that Bruker doesn't really plan to make much money from software, they just want the software to support and help boost hardware sales. However the service contract is a big portion of the cost. That's expensive.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.